相关实验视频
Updated: Jan 28, 2026

09:44
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
19.8K
完全的突然重定位:超越第一通道效应还有希望
Manuel Requena1,2,3, Álvaro García-Tornel1,3, Isabel Rodríguez4
1Unitat d'Ictus Hospital Universitari Vall d'Hebron Barcelona Spain.
Stroke (Hoboken, N.J.)
|January 26, 2026
概括
在接受内血管治疗的中风患者中,完整的突然再通道 (cSR) 与更好的结果有关. 这种在一次通过中实现的模式,独立地预测了有利的功能结果,无论通过的总数有多少次.
科学领域:
- 神经学 神经学
- 干预性放射学 干预性放射学
- 心血管疾病 心血管疾病
背景情况:
- 血管内治疗的目的是快速,在中风患者的完整的再通道化.
- 每次通过一次重新通道的模式对于程序的成功至关重要.
研究的目的:
- 为了研究每次通道再通道化模式对最终完全再通道化患者的结果的影响.
- 为了确定完整的突然再通道 (cSR) 是否与改善的功能结果有关.
主要方法:
- 对400名患有内动脉或M1-中脑动脉封闭症的患者进行了回顾性分析.
- 定义完整的突然再通道 (cSR) 是在脑梗塞 (eTICI) 2c-3中实现扩大血栓溶解的一次通过.
- 在cSR和完整的渐进性重新道化组之间比较结果.
主要成果:
- 75%的患者 (301/400) 获得了cSR.
- 对于cSR组来说,通过次数较少 (1对2) 和时间较短 (27对46分钟).
- 在90天后,cSR是良好的功能结果的独立预测因素 (57.8%与44.4%,aOR1.72).
结论:
- 完整的突然再通道 (cSR) 是中风患者的大血管封闭的良好结果的重要预测因素.
- 对cSR对结果的积极影响与所需的血栓切除术总次数无关.
相关概念视频
First Pass Effect
9.1K
Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
9.1K
Single-pass Transmembrane Proteins
6.6K
Integral membrane proteins are tightly associated with the cell membrane and play a crucial role in cell communication, signaling, adhesion, and transport of the molecules. Some integral membrane proteins are present only in the membrane monolayer. For example, the enzyme fatty acid amide hydrolase is present in the cytoplasmic side of the membrane monolayer. In contrast, another type of integral membrane protein, also known as a transmembrane protein, spans across the membrane. Transmembrane...
6.6K
Factors Influencing Bioavailability: First-Pass Elimination
8.1K
When a drug is taken orally, it undergoes a journey starting from the gastrointestinal (GI) tract, passing through the portal vein, reaching the liver, and finally entering the systemic circulation. This process involves the absorption of the drug across the GI tract. The liver is the primary site for metabolizing the drug, with some metabolism also occurring in the gut wall. This journey significantly reduces the quantity of the drug that reaches the systemic circulation, a phenomenon known as...
8.1K
Insertion of Single-pass Transmembrane Proteins in the RER
18.0K
Integral membrane proteins are proteins adhered to the lipid bilayer of a cell organelle or membrane. They can be of two types: transmembrane integral proteins that span the lipid bilayer and monotopic proteins that are attached to either side of the membrane but do not pass through it.
Integral transmembrane proteins possess transmembrane and extra membrane domains. The transmembrane domains are primarily made of 20-25 hydrophobic amino acids arranged in a helical secondary confirmation. These...
Integral transmembrane proteins possess transmembrane and extra membrane domains. The transmembrane domains are primarily made of 20-25 hydrophobic amino acids arranged in a helical secondary confirmation. These...
18.0K
Insertion of Multi-pass Transmembrane Proteins in the RER
18.3K
The rough ER membrane synthesizes, assembles, and embeds transmembrane proteins in diverse topologies. These proteins function as transporters or channels and can remain in the ER membrane or are sent to the Golgi complex, lysosome, and cell membrane.
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
18.3K
Multi-pass Transmembrane Proteins and β-barrels
6.5K
In multi-pass transmembrane proteins, the polypeptide chain crosses the membrane more than once. The transmembrane polypeptide chain either forms an α-helix or β-strand structure. α-Helix containing multi-pass transmembrane proteins are ubiquitous, whereas β-strand containing ones are mainly found in gram-negative bacteria, mitochondria, and chloroplasts.
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as...
α-Helix containing multi-pass transmembrane proteins
Multi-pass transmembrane proteins such as...
6.5K

